Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan DDI with Midazolam, Fexofenadine, and MMF
NCT03108274Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area Under The Plasma Concentration-time Curve From Time 0 To The Time Of The Last Observed Non-zero Concentration, Area Under The Plasma Concentration-time Curve From Time 0 Extrapolated To Infinity and 2 more. Started Apr 2017; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03108274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108274.